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Abstract
Context: Human NR5A1/SF-1 mutations cause 46,XY disorder of sex development (DSD) with broad phenotypic variability,
and rarely cause adrenal insufficiency although SF-1 is an important transcription factor for many genes involved in
steroidogenesis. In addition, the Sf-1 knockout mouse develops obesity with age. Obesity might be mediated through Sf-1
regulating activity of brain-derived neurotrophic factor (BDNF), an important regulator of energy balance in the
ventromedial hypothalamus.
Objective: To characterize novel SF-1 gene variants in 4 families, clinical, genetic and functional studies were performed
with respect to steroidogenesis and energy balance.
Patients: 5 patients with 46,XY DSD were found to harbor NR5A1/SF-1 mutations including 2 novel variations. One patient
harboring a novel mutation also suffered from adrenal insufficiency.
Methods: SF-1 mutations were studied in cell systems (HEK293, JEG3) for impact on transcription of genes involved in
steroidogenesis (CYP11A1, CYP17A1, HSD3B2) and in energy balance (BDNF). BDNF regulation by SF-1 was studied by
promoter assays (JEG3).
Results: Two novel NR5A1/SF-1 mutations (Glu7Stop, His408Profs*159) were confirmed. Glu7Stop is the 4th reported SF-1
mutation causing DSD and adrenal insufficiency. In vitro studies revealed that transcription of the BDNF gene is regulated by
SF-1, and that mutant SF-1 decreased BDNF promoter activation (similar to steroid enzyme promoters). However, clinical
data from 16 subjects carrying SF-1 mutations showed normal birth weight and BMI.
Conclusions: Glu7Stop and His408Profs*159 are novel SF-1 mutations identified in patients with 46,XY DSD and adrenal
insufficiency (Glu7Stop). In vitro, SF-1 mutations affect not only steroidogenesis but also transcription of BDNF which is
involved in energy balance. However, in contrast to mice, consequences on weight were not found in humans with SF-1
mutations.
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Introduction
The nuclear receptor steroidogenic factor 1 (SF-1/NR5A1) is a
master regulator of adrenal and gonadal development, including
sexual determination and differentiation, as well as steroidogenesis
and reproduction [1,2]. SF-1 also plays a pivotal role in the
development of the ventromedial hypothalamic nucleus (VMH)
and for functions of the pituitary gland [3,4]. In addition,
expression of SF-1 has been identified in the spleen, skin and in
small amounts in the placenta [5,6,7]. SF-1 was first identified in
1992 for its function as a transcriptional regulator of steroidogenic
genes and was named accordingly [8]. Later, the Sf-1 KO mice
were reported with a severe phenotype including lack of adrenal
glands and a complete sex reversal of 46,XY animals [9]. Finally in
1999, the first human being with adrenal insufficiency and 46,XY
disorder of sexual development (DSD) harboring a heterozygote
SF-1 mutation was described [10]. Meanwhile, numerous SF-1
mutations have been identified [2], yet the exact function of SF-1
explaining the broad phenotype associated with SF-1 mutations
remains elusive [11,12].
SF-1 is encoded by the NR5A1 gene which is located on the
long arm of chromosome 9 (9q33). The gene consists of 7 exons
but only 6 exons are coding. SF-1 has 461 amino acids and
comprises a DNA binding domain with two zinc fingers, an
accessory DNA binding domain, a hinge region and a ligand
binding domain [1]. The structure of SF-1 is greatly conserved
among animal species [13]. To date more than 70 human NR5A1
mutations have been described (Human Gene Mutations Data-
base, www.hgmd.cf.ac.uk). Most of these mutations are found in a
heterozygote state [11,14] and only a few in a homozygote [15], or
compound heterozygote state [16]. So far, no correlation between
phenotype and genotype, and also no clear pattern of heredity has
been seen as both sporadic and familiar presentations exist [11].
Furthermore, possibility of dominant negative effect of heterozy-
gote NR5A1 mutations has been debated without convincing
results [11].
The clinical presentation of SF-1 deficiency is very variable.
The first human individual with a heterozygote Gly35Glu SF-1
mutation had 46,XY DSD and adrenal insufficiency [10]. So far,
only two additional SF-1 mutations causing adrenal insufficiency
have been reported [15,17]. The heterozygote Arg255Leu
mutation was found in a girl with symptoms of adrenal
insufficiency and normal ovarian differentiation and function
[17], and the homozygote Arg92Gln mutation was present in a
boy with adrenal failure and 46,XY DSD [15]. By contrast,
NR5A1 mutations are frequently found in patients with 46,XY
DSD with apparently normal function of the adrenal cortex
[11,14,18]. Similarly, some NR5A1 mutations were found in
46,XX females with premature ovarian failure or ovarian
insufficiency with normal adrenal function [11,19].
SF-1 deficiency also affects the central regulation of reproduc-
tion and energy balance [20]. The pituitary Sf-1 KO mouse model
showed that SF-1 is an essential regulator of gonadotropin (LH,
FSH) expression [4,21,22]. These mice present with hypogonad-
otropic hypogonadism reflected by sexual immaturity, low weight
of gonads and sterility [4]. Apart from the pituitary gland, SF-1 is
also required for the development, organization and function of
the ventromedial hypothalamus (VMH) [3,23]. Mouse models
have shown that a loss of SF-1 stimulation leads to disorganization
of the VMH, thereby impairing its function related to anxiety,
thermoregulation, sexual behavior and energy balance [24].
Selective deletion of Sf-1 in the VMH in mice prenatally resulted
in late onset obesity [25], while the same deletion postnatally led to
diet induced obesity and deregulated thermogenesis [25]. How-
ever, these possible effects of SF-1 deficiency have not yet been
studied in humans harboring SF-1 mutations.
In this context, the brain-derived neurotrophic factor (BDNF) is
an important regulator of energy balance [26]. It is a highly
conserved neurotrophin which is thought to be a SF-1 target gene
[27]. BDNF is expressed in several appetite-regulating centers in
the hypothalamus and the hindbrain in both mouse and human
[28]. Depletion of Bdnf or its receptor (TrkB) in mice results in
excessive feeding, weight gain and features accompanied by the
metabolic syndrome [26,29]. Abnormal locomotor activity and
late-onset obesity was also observed in a Bdnf heterozygote
knockout mouse model or when Bdnf was inactivated in the
central nervous system [29,30]. In addition, reduced expression of
BDNF was described in association with obesity in the leptin
receptor deficient mouse [31], the Alzheimer disease mouse [32]
and the Sf-1 KO mouse [3]. In humans, two reports show a
relationship between BDNF (locus 11p14) and obesity [33,34].
Patients with WAGR syndrome (Wilm’s tumor, aniridia, genito-
urinary anomalies and mental retardation, OMIM 194072) with a
heterozygous 11p14 deletion including the BDNF gene suffer all
from childhood onset obesity, while WAGR syndrome patients
without genetic anomalies including the BDNF gene have normal
prevalence of obesity [33]. Additionally, a girl with obesity and
impaired cognitive function who has only one functional copy of
the BDNF gene has been described [34].
We hypothesize that human SF-1 mutations may affect
metabolism and that this effect could be mediated in part through
BDNF. Therefore, in this study we characterize novel NR5A1
mutations, one being associated with the rare phenotype of
adrenal insufficiency and 46,XY DSD. We describe the effect of
these SF-1 mutations in vitro on transcription of genes involved in
steroidogenesis and on the BDNF gene which is important for
central regulation of food intake. Finally, we describe some weight
related parameters in our small cohort of NR5A1 patients.
Patients and Methods
Patients and ethical approval
Five patients of Czech Republic and Spanish origin with
unsolved 46,XY DSD were studied. Main characteristics of
patients and families are shown in Table 1, family trees are
depicted in Figure 1A and biochemical data are available as Table
S1. All studied subjects and/or their legal guardians gave written
informed consent for the hormonal and molecular studies, which
were approved by the respective ethical committees of the involved
centers: Ethics commissions of Vall d’Hebron Research Institute
and CIBERER, Barcelona, Spain, and University Hospital Bern,
Switzerland.
Case reports (Table 1 and 2, Figure 1, Table S1)
Patient 1 from Czech Republic, was delivered at 31 weeks
gestation because of HELLP (hemolysis, elevated liver enzymes,
low platelets) syndrome of the mother. Birth weight was 1430 g (5–
10th percentile) and length was 38 cm (5–10th percentile). Physical
exam revealed perineal hypospadias but no other anomalies.
Karyotype was 46,XY. Neonatal period was unremarkable.
However, at the age of three months, he was admitted for adrenal
failure (hyponatremia, hyperkalemia, episode of hypoglycemia,
dehydration) in the course of an acute, viral respiratory infection.
Baseline levels of ACTH and plasma renin activity were elevated.
Cortisol response to ACTH stimulation was low confirming
adrenal insufficiency.
Human SF-1, Steroidogenesis and Energy Balance
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Patient 2 from Spain (with parents from Argentina of European
descents) was investigated during fetal development because of a
discordant genital sex by ultrasound (female) compared to the
genetic sex (46,XY). He was conceived by ICSI from both parents
gametes. Owing to the father‘s history of hypospadias, the NR5A1
gene was analysed in the father showing an heterozygous
mutation. The same mutation was detected in fetal material.
Although there was no consanguinity, the mother was also
analysed to predict possible compound heterozygocity or homo-
zygocity. The patient was delivered at 40 weeks gestation with a
normal weight and length. External genitalia showed a clitoris-like
genital tubercle, posterior labial fusion, no visible urethral meatus
nor vaginal opening. Small (,1 ml) gonads were palpable in the
genital folds. Male sex was assigned. The neonatal period was
uneventful and endocrine evaluation was not performed until the
age of 3.5 months when baseline ACTH, cortisol and 17-hydroxy-
progesterone (17OHP) were normal, while baseline testosterone
(T) was low and FSH high for age; T response to hCG stimulation
was low. Therefore, at 4 months of age, gender was reassigned to
female due to the severely feminized external genitalia.
Patient 3 from Spain was delivered at 38 weeks gestation with
normal weight and length; he was evaluated at 14 days due to
ambiguous genitalia (scrotal hypospadias, penis length 2 cm and
gonads palpable in the scrotal folds). Karyotype was 46,XY.
Baseline cortisol and aldosterone were normal as were the
measured steroid precursors. Baseline FSH was slightly elevated,
AMH and inhibin B were low. T response to hCG stimulation was
low while the T/DHT ratio was normal.
Patients 4 and 5 from Spain were delivered as bichorionic twins
at 36 weeks gestation with the 1st twin showing normal weight and
lenght while the 2nd was small for gestational age (SGA). They
were obtained by ICSI from the father’s sperm and a donated ova
to avoid the mother’s genetic disease (epidermiolysis bullosa). Both
babies presented with ambiguous genitalia: scrotal hypospadias
with a penis length of 1.5 cm, both gonads palpable (1 ml) in the
scrotal folds (1st twin) and unilateral cryptorchidism and one
palpable gonad (0.5 ml in the 2nd twin). The father had been
operated for hypospadias during childhood. His testes biopsies at 9
years of age revealed diminished seminiferous tubule diameter and
fertility index in the left testis while these parameters were normal
in the right testis). Neonatal period was uneventful in both twins.
At birth (2 days), baseline T, precursors and gonadotropins were
normal for age and AMH was low at 2 months.
Genetic analyses
Genomic DNA was isolated from peripheral blood leukocytes.
All exons and part of adjacent introns of the NR5A1 gene were
amplified and sequenced as previously described [11]. Obtained
sequences were analysed against the NR5A1/SF-1 GenBank
entries NT_008470.19 (genomic DNA), NM_004959.4 (mRNA)
and NP_004950.2 (protein).
In vitro functional studies
Human embryonic kidney cells (HEK293) and human placental
choriocarcinoma cells (JEG3) were used for functional studies.
HEK293 cells were cultured in DMEM supplemented with 10%
fetal calf serum, 1% penicillin/streptomycin and 1% sodium
pyruvate (Gibco, Paisley, UK). JEG3 cells were cultured in MEM
supplemented with 10% fetal calf serum, 1% penicillin/strepto-
mycin and 1% L-glutamine (Gibco).
Figure 1. Genetic information on 5 subjects carrying NR5A1 mutations. A. Family trees of 4 families and 7 affected individuals (5 patients and
2 parents) are shown. Scheme of the NR5A1 gene showing the mutations identified in the reported patients (above the scheme) and all reported SF-1
mutations causing adrenal insufficiency (below the scheme). Electropherograms of novel mutations are also depicted. The NR5A1 gene is composed
of coding (black) and non-coding sequences (gray). Exons are indicated by numbers.
doi:10.1371/journal.pone.0104838.g001
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Promoter luciferase reporter vectors for steroidogenic enzymes
HSD3B2, CYP11A1, CYP17A1 (-227CYP17A1_Dluc, -152CY-
P11A1_pGL3, -301HSD3B2_pGL3) and corresponding empty
control vectors (D_luc, pGL3), as well as cDNA for wild-type (WT)
SF-1/NR5A1 were available from previous work [35,36].
Luciferase reporter vectors for human promoters I, IV, V and
VII of the BDNF gene (pGL4.15_hBDNFpI, pGL4.15_
hBDNFpIV, pGL4.15_hBDNFpV, pGL4.15_hBDNFpVII) were
kindly provided by Dr. P. Pruunsild and Prof. T. Timmusk
(Tallinn University of Technology, Tallinn, Estonia). Mutant
NR5A1 expression vectors (c.19T, c.887T, c.937T, c.1222_
1223insC) and SF-1 cis element mutant pGL4.15_hBDNFpI (c.-
876_873CTTT) were generated by PCR-based site-directed
mutagenesis using specific primers (available upon request)
following the QuickChange protocol by Stratagene (Agilent
Technologies Inc., Santa Clara, CA, USA).
For promoter activity studies, cells were cultured in 24-well
plates and transiently transfected with WT or mutant NR5A1 and
WT or mutant promoter luciferase reporter constructs using
Lipofectamine 2000 (Invitrogen, AG, Basel, Switzerland) for 48
hours, and the Dual-Luciferase Reporter (DLR) Assay System
(Promega AG, Wallisellen, Switzerland) was used for readout as
previously described [11]. Specific Firefly luciferase readings were
normalized against Renilla control readings and expressed as
relative light units (RLU). Experiments were repeated at least 3
times in duplicates.
Statistical analysis
Data are shown as mean6SEM of at least three independent
experiments. Statistical analysis was examined by t-test with
Microsoft Office Excel (Windows 2003, Microsoft Inc.). Signifi-
cance was set at *p,0.05, **p,0.01.
Results
Genetic analysis
We identified 2 novel and 2 known NR5A1 sequence variations
in 5 patients newly diagnosed with SF-1 deficiency (Figure 1).
Patient 1 (family 1), a boy with adrenal insufficiency and 46,XY
DSD harbored compound heterozygote novel c.19G.T and
c.887C.T variations in the NR5A1 gene coding for Glu7Stop in
the DNA binding domain and Thr296Met in the ligand binding
domain. Glu7Stop was not found in either parents, thus qualifying
as a de novo mutation. By contrast, heterozygocity for Thr296Met
was detected in the healthy father (Figure 1). Patient 2 (family 2)
was heterozygote for a novel insertion c.1222_1223insC which is
predicted to result in a frameshift elongating the SF-1 protein by
159 amino acids (His408Profs*159). The mutation was inherited
from an affected carrier father (Figure 1). In patients 3 to 5 from
two families (3 and 4), a heterozygote c.937C.T mutation in exon
5 was found changing Arg313Cys in the ligand-binding domain
(Table 1, Figure 1). In family 3, the mutation was de novo (patient
3), whereas in family 4 (patients 4 and 5), the mutation was
inherited in two dizygotic twins from an affected carrier father
(Table 1, Figure 1). This mutation was recently reported in a
patient manifesting with distal hypospadias and a bifid scrotum
containing testes [37].
In vitro studies of the impact of SF-1 variants on
steroidogenesis and energy balance
Impact of identified SF-1 mutations on steroidogenesis was
studied in non-steroidogenic HEK293 cells by assessing their
transcriptional activity on the promoters of the HSD3B2,
CYP11A1 and CYP17A1 genes (Figure 2). The Glu7Stop
mutation revealed a complete lack of transcriptional activation
for all promoter constructs. The Thr296Met variant showed
similar transactivation activity as WT SF-1 indicating that it is not
a disease-causing variant but rather a polymorphism (SNP).
Interestingly, the His408Profs*159 and Arg313Cys mutations
showed normal activity when tested on the HSD3B2 promoter
construct, but their transactivation activity was significantly
decreased when tested on the CYP11A1 and CYP17A1 promot-
ers.
To study potential involvement of SF-1 on central energy
balance, the transcriptional regulation of SF-1 on the promoters of
the BDNF gene was assessed in JEG3 cells. According to
literature, there are many alternative BDNF variants (17 BDNF
and 12 antisense BDNF variants) in human due to use of different
promoters [28]. For initial experiments, we used four different
human BDNF promoter constructs, namely hBDNF I, IV, V and
VII. Promoter constructs I and IV were chosen as mouse Bdnf
transcripts I and IV are primarily expressed in the brain (area of
VMH) and their promoters are reported to be regulated by Sf-1
[27]. Similarly, promoters V and VII were assessed for reported
expression in the human brain [28]. In our JEG3 cell system,
among those promoters, we were only able to transactivate the
hBDNF promoter I by WT SF-1 (data not shown). Thus, further
studies involving SF-1 and human BDNF were performed with
this hBDNF promoter I (Figure 3). In this promoter, we found a
putative SF-1 cis-element at c.-874 to -867 (CAAGGACA). To
confirm that this cis-element in the hBDNF promoter is regulated
by SF-1, we constructed a promoter with a mutant SF-1 site and
assessed its activity by co-transfection with WT SF-1. Upon co-
transfection with WT SF-1, the mutant BDNF promoter lost
activity when compared with the WT promoter (Figure 3A). In
this system, SF-1 mutants Glu7Stop, Arg313Cys and His408-
Profs*159 showed only weak transactivation activity compared to
WT SF-1 confirming a possible effect of SF-1 on BDNF and thus
energy balance. By contrast, the Thr296Met sequence variation
had similar transactivation power on the hBNDF promoter I as
seen with WT SF-1 (Figure 3B).
Weight related parameters of patients harboring SF-1
mutations
To address the question whether SF-1 deficiency may have
metabolic consequences, we collected clinical data from our cohort
of patients with SF-1 mutations. We were able to obtain data from
16 subjects with heterozygote SF-1 mutations including patients
and their (affected) relatives (Table 2). Birth weight in singletons
was normal (n = 8; median20.83 SD, range21.9 to 1.21). BMI of
subjects currently being 1–17 years of age was also normal (n = 9;
median 0.04 SD, range 20.69 to 2.81), as was BMI of 5 adults
(median 0.6 SD, range 0.4 to 0.84). Thus in our small cohort of
rather young patients with heterozygote SF-1 mutations over-
weight or obesity seems not an issue.
Discussion
In this study, two novel SF-1 mutations (Glu7Stop, His408-
Profs*159) were identified in 5 patients with SF-1 deficiency, all
manifesting with 46,XY DSD and one (Glu7Stop) presenting with
adrenal insufficiency that is rarely associated with SF-1 mutations.
The disease causing impact of the identified mutations was
confirmed by functional studies in cell models assessing transcrip-
tional activity of wild-type and mutant SF-1 on genes involved in
steroidogenesis (CYP11A1, CYP17A1, HSD3B2) and central
energy balance (BDNF).
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To date, only three SF-1 mutations have been implicated with
adrenal insufficiency (heterozygote Gly35Glu and Arg255Leu,
homozygote Arg92Gln) [10,15,17]. With patient 1, we add a novel
SF-1 mutation (Glu7Stop) to this series. Our in vitro studies
suggest that Glu7Stop is a loss of function SF-1 mutation. By
contrast, the second SF-1 sequence variation (Thr296Met)
identified in patient 1 is rather a simple polymorphism. First, it
does not differ in functional assays when compared to WT SF-1.
Second, this variant (rs201151141) has also been detected at an
allelic frequency of 0.001 in a cohort of 662 normal subjects
studied for a large-scale genome sequencing project (dbSNP
database, http://www.ncbi.nlm.nih.gov/projects/SNP/snp).
The novel His408Profs*159 mutation identified in the SF-1
gene in patient 2 codes for a longer protein of 567 amino acids
compared to WT SF-1 (461 aa). This mutant had an impact on
both the steroidogenic promoters and the BDNF promoter
(Figure 2). Interestingly, this heterozygous mutation was first
detected in the father when investigated because of his history of
childhood hypospadias and infertility. He nevertheless fathered a
child through ICSI but the fetus’s genetic and phenotypic sex was
discordant. At birth the 46,XY child’s genital phenotype was
almost completely feminized and hormonal work-up at 4 months
of age revealed low androgens prompting female sex assignment
although the mutation was the same as in the father. This
illustrates again for a novel NR5A1 mutation the wide phenotypic
spectrum within the same family.
The Arg313Cys mutation found in patients 3–5 in our study
was recently reported in a patient with hypospadias [37]. Similar
to our functional assays, Arg313Cys showed reduced transactiva-
tion on the promoters of the AMH and CYP11A1 genes [37].
Although Arg313 is located in the highly conserved helix 5 of the
ligand-binding domain, this same position has also been described
for an Arg313His change (c.838G.A) in males with hypospadias
[38,39]. Thus, position Arg313 of SF-1 may be a hot spot for
mutations. Interestingly, this mutation appeared de novo in our
family 4, while in family 5, the mutation was transmitted by an
affected father.
In theory, SF-1 mutations could also have metabolic conse-
quences for affected patients. But so far, no clinical data existed on
this topic. Observations from the Sf-1 KO mice models suggest
that loss of SF-1 is associated with impaired energy balance and
low temperature expenditure leading to late-onset type of obesity
[25]. Deletion of BDNF gene was described in obese patients with
WAGR syndrome [33]. Among many other factors regulating
appetite, SF-1 together with BDNF are expressed in the VMH of
mice. Tran et al. described a significantly decreased expression of
the Bdnf gene in Sf-1 +/2 KOmice [27]. They also identified two
promoter variants of the murine Bdnf gene which were specifically
used in the VMH and their activity was related to SF-1 dosage
[27]. In the presented study, we tried to establish the role of SF-1
in the regulation of human BDNF, an important player for central
energy balance and thus obesity [40]. In fact, our experiments now
show that the human BDNF promoter I is regulated by SF-1, and
that SF-1 mutations have impaired transactivation activity on this
promoter similar to impaired effect on promoters regulating genes
of steroidogenesis. These results indicate that SF-1 might be a co-
regulator of energy balance and that mutations in SF-1 may
therefore also lead to metabolic consequences (e.g. obesity) in
humans.
In addition to the in vitro studies, we were also able to collect
some clinical data related to energy balance in 16 patients with
heterozygote SF-1 mutations (Table 2). However, in our small
cohort of 9 patients aged 1–17 years and 5 adults, we did not find
weights and BMIs consistent with overweight or obesity.
Figure 2. Promoter reporter studies for reported NR5A1
mutations. Human embryonic kidney HEK293 cells were transiently
transfected with wild-type (WT) or mutant SF-1 and promoter luciferase
reporter constructs of the genes for steroidogenic enzymes HSD3B2 (A),
CYP11A1 (B), CYP17A1 (C). Luciferase activity was measured with the
Promega Dual Luciferase assay system. Results are expressed as
percentage of WT SF-1 activity. Independent experiments were
performed in duplicate at least 3 times. Error bars represent the mean
and SEM. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0104838.g002
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Therefore, presented clinical data in humans are not in line with
data found in mice [25,26], although in vitro data in human and
mouse are similar [25,27]. These negative results might be ‘true’
negative results or may be explained by the following shortcomings
of our presented study. First, small number of studied patients,
which are in addition too young to observe metabolic conse-
quences. Second, all patients are heterozygote for their SF-1
mutation and carry one wild-type SF-1 allele while most studied
mice were Sf-1 complete KO. Further collaborative studies are
therefore needed to gather clinical data of more patients and
follow-up on a bigger cohort longitudinally.
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study. Values outside the age- and sex-specific reference range
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